Before you start treatment with Ibrance, tell your doctor and pharmacist ... the drug may not work to treat your breast cancer. It’s also possible for Ibrance to interact with turmeric.

Itovebi, combined with Ibrance and Faslodex, is approved for specific advanced breast cancer cases with PIK3CA mutations ... The Itovebi combination regimen was approved in October 2024 for the ...

Vepdegestrant (ARV-471) yielded a statistically significant and clinically meaningful improvement in progression-free ...

Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

NICE has rejected Pfizer’s Ibrance breast cancer drug in first draft guidance, citing the treatment's high cost. The decision confirms the company’s fears that the drug would fare badly under ...

This stage of breast cancer is considered incurable and treatment options are limited, with only 15% of patients living beyond five years. CDK4/6 inhibitor Ibrance has been available since 2020 to ...

The Breast Cancer market is undergoing significant expansion, driven by increasing disease prevalence and the introduction of innovative therapeutic options from companies such as ...

Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant ...

Healthcare stocks have been out of vogue with investors since late 2022. Myriad reasons underlie the negative sentiment ...

Pfizer’s (PFE) stock has fallen ill since the COVID-19 pandemic waned, and it is still experiencing some aftereffects. The ...

The approval of CDK4/6 inhibitors has significantly transformed the treatment landscape for HR+/HER2− breast cancer. Currently, five selective CDK4/6 inhibitors—ENHERTU, DATROWAY, IBRANCE ...

Based on Intelligencia AI’s comprehensive, proprietary database of over 20,000 industry-sponsored, interventional oncology clinical programs (around 12,400 clinical trials), recent insights highlight ...